
Reza Khosravan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4397960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment. American Journal of Therapeutics, 2005, 12, 22-34.	0.9	140
2	Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects. Clinical Pharmacokinetics, 2006, 45, 821-841.	3.5	85
3	The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase. Journal of Clinical Pharmacology, 2006, 46, 88-102.	2.0	68
4	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. British Journal of Clinical Pharmacology, 2008, 65, 355-363.	2.4	67
5	Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function. Journal of Clinical Pharmacology, 2010, 50, 472-481.	2.0	66
6	Metabolism and Excretion of [¹⁴ C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects. Journal of Clinical Pharmacology, 2011, 51, 189-201.	2.0	51
7	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2018, 107, 237-245.	2.5	37
8	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clinical Pharmacokinetics, 2016, 55, 1251-1269.	3.5	29
9	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a nonâ€purine selective inhibitor of xanthine oxidase. British Journal of Clinical Pharmacology, 2010, 70, 57-64.	2.4	19
10	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. Cancer Chemotherapy and Pharmacology, 2019, 84, 41-50.	2.3	18
11	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. AAPS Journal, 2020, 22, 31.	4.4	11
12	A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status Journal of Clinical Oncology, 2012, 30, 363-363.	1.6	9
13	Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 181-192.	2.3	7
14	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. Cancer Chemotherapy and Pharmacology, 2021, 87, 621-634.	2.3	3
15	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 343-352.	1.6	2